Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD

Journal of Bone and Mineral Research

Volumn 20, Issue 12, 2005, Pages 2097-2104

  Watts, Nelson B ^a   Geusens, Piet ^b,c   Barton, Ian P ^d   Felsenberg, Dieter ^e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b HASSELT UNIVERSITY   (Belgium)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bone mass; Nonvertebral fractures; Osteoporosis; Risedronate; Surrogate measure

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D;

AGE; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; INCIDENCE; LUMBAR SPINE; META ANALYSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; VITAMIN INTAKE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE III; ETIDRONIC ACID; FEMALE; FEMUR NECK; FRACTURES, BONE; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 28144450564     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050814     Document Type: Article

References (42)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795.
2. National Osteoporosis Foundation 2005 America's Bone Health: The state of Osteoporosis and low bone mass. Available at http://www.nof.org/advocacy/ prevalence/. Accessed July 18, 2005.
3. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL 1992 Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005-1010.
4. Food and Drug Administration 2005 Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Available at http:// www.fda.gov/cder/guidance/osteo.pdf. Accessed July 18, 2005.
5. Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026.
6. Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre JM, Abadie E, Lekkerkerker F 2002 Uncertain future of trials in osteoporosis. Osteoporos Int 13:443-449.
7. Khosla S 2003 Surrogates for fracture endpoints in clinical trials. J Bone Miner Res 18:1146-1149.
8. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, Rosen C 2002 Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 31:659-679.
9. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D for the Fracture Intervention Trial Research Group 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246-1254.
10. Li Z, Chines AA, Meredith MP 2004 Statistical validation of surrogate endpoints: Is bone density a valid surrogate for fracture? J Musculoskel Neuron Interact 4:64-74.
11. Delmas PD, Li Z, Cooper C 2004 The relationship between changes in bone mineral density and fracture risk reduction with anti-resorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330-337.
12. Delmas PD, Seeman E 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604.
13. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
14. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
15. Wasnich R, Miller PD, Chesnut CH, Huss H, Wilson K, Schimmer RC 2003 Changes in bone mineral density as a predictor of vertebral fracture efficacy with ibandronate: Results from a phase III fracture study. J Bone Miner Res 18:S2;S160.
16. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
17. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 The relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261.
18. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401.
19. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, for the Fracture Intervention Trial Study Group 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258.
20. Blake GM, Wahner HW, Fogelman I 1999 The Evaluation of Osteoporosis: Dual Energy X-Ray Absorptionmetry and Ultrasound in Clinical Practice, 2nd ed. Martin Dunitz Ltd, London, UK.
21. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592.
22. Barton I 2004 The relationship between osteoporotic fracture risk and a surrogate: Apparent discrepancies between analyses based on individual patient data and summary statistics. Pharm Stat 3:205-212.
23. Li Z, Meredith MP 2003 Exploring the relationship between surrogates and clinical outcomes: Analysis of individual patieht data vs. meta-regression on group-level summary statistics. J Biopharm Stat 13:777-792.
24. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD for the Vertebral Efficacy With Risedronate Therapy Study Group (VERT) 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344-1352.
25. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R on behalf of the Vertebral Efficacy With Risedronate Therapy Study Group (VERT) 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91.
26. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY for the Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340.
27. Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175-3188.
28. Freedman LS, Graubard BI, Schatzkin A 1992 Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167-178.
29. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R 1998 Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489.
30. Hochberg MC, Miller PD, Wasnich RD, Ross PD, Greenspan S 2004 Letter to the editor. Bone 35:1222-1224.
31. Delmas PD, Seeman E 2004 Response to letter to the editor. Bone 35:1225-1226.
32. Chen C, Wang H, Snapinn SM 2003 Proportion of treatment effect (PTE) explained by a surrogate marker. Stat Med 22:3449-3459.
33. Thompson SG, Higgins JP 2005 Treating individuals 4: Can meta-analysis help target interventions at individuals most likely to benefit? Lancet 365:341-346.
34. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
35. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas P 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249.
36. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
37. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
38. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
39. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930.
40. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
41. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD 2004 Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736-746.
42. Jiang Y, Zhao J, Geusens P, Liao EY, Adriaensens P, Gelan J, Azria M, Boonen S, Caulin F, Lynch JA, Ouyang X, Genant HK 2005 Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation. J Bone Miner Res 20:125-130.